
VOTING PANEL



IAN RESTALL FLATHILL COMMUNICATIONS (VOTING PANEL CHAIRMAN)

Throughout his career, Ian has been involved in the quoted growth companies sector. His early career was as a stockbroker, analyst, broadcaster and financial journalist in this area and, since founding The Design Portfolio Marketing Services in 1991, he has been active in helping many companies in this sector with their investor communication and corporate reporting requirements. Ian is also Chairman of Flathill Communications Group plc, President of The Design Portfolio Marketing Services Inc. and a member of the Investor Relations Society.

METTE KIRSTINE AGGER LUNDBECKFOND VENTURES

Mette is Managing Partner in Lundbeckfond Ventures, an evergreen life science venture fund. Mette has more than 20 years of broad international experience within biotech/life science covering business development and licensing, management and financing. She was previously co-founder and CEO of 7TM Pharma. Prior to that she was part of the management team of NeuroSearch A/S responsible for business development and licensing and has over the years co-founded several biotech companies. She started her career as Patent Agent. Mette has been appointed to numerous board positions both in private and public companies. Mette graduated with a degree in Biology from the University of Copenhagen and has an MBA.

VOTING PANEL



AMBER BIELECKA CONSILIUM STRATEGIC COMMUNICATIONS

Amber is a healthcare communications specialist and co-founder of Consilium Strategic Communications. She has extensive experience in providing strategic communications support to some of the healthcare sector's leading companies and has delivered successful PR campaigns, including significant sector IPOs, M&A and public and private fundraisings, across Europe and North America. Prior to founding Consilium, Amber was a member of M:Communications' healthcare team and the Pharma & Biotech team at Citigate Dewe Rogerson. Amber also has a strong background in public affairs and lobbying, with experience from the European Parliament in Brussels, and the US Senate in Washington.

MARY CLARK HUME BROPHY

Mary is head of Hume Brophy's International Healthcare IR & PR practice. She has over 20 years' experience in strategic corporate and financial communications. She specialises in advising healthcare companies on all aspects of their financial and corporate communications. She has a wealth of experience in corporate positioning, M&A, IPOs and fundraisings. She has worked with over 30 healthcare clients across ten European countries.

Mary was previously Head of Healthcare at Capital MS&L. Prior to this she was Head of the European Consulting team at Thomson Reuters, the world's largest investor relations company, where she advised a large number of companies on investor relations strategies, and all aspects of corporate and financial communications. She started her career at BTG plc where she was Director of Corporate Communications and Investor Relations.

Mary has been regularly highly ranked in the top professionals in the Extel investor relations survey voted by leading institutional investors and sell-side analysts.

VOTING PANEL



DR LUCINDA CRABTREE PANMURE GORDON

Lucinda is Director of Pharmaceuticals, Bio and Healthcare Sales at Panmure Gordon. She has a range of experience working in the Finance Sector in Equity Research roles, including the European Healthcare Team at Goldman Sachs and the European Biotech team at Jefferies, and within the Pharmaceutical/Biotechnology Industry (across large and small healthcare businesses).

She received a first class degree in Pharmacology and Physiology and a PhD in Neuropharmacology, both from University College London. After ten years' experience, she joined Panmure Gordon in May last year to lead specialist sales of the healthcare sector.

VICTORIA DARBYSHIRE JP MORGAN

Victoria joined JP Morgan Asset Management in the European Research team covering the healthcare sector seven years ago after starting in the investment bank in 2004. She also contributes to the JP Morgan Global Healthcare Fund. Victoria achieved a top three ranking in the 2013 Extel buyside survey in both the Pharma & Biotech and Medtech sectors. She became a CFA charterholder in 2009 and has a BSc in Chemistry from Durham University.

VOTING PANEL



AMIT DRACH SPHERA GLOBAL HEALTHCARE FUND

Amit is Senior Scientific Analyst at Sphera Global Healthcare Fund. His earlier experience includes two years as business development and pipeline manager at ATI technological incubator, and four years in marketing, sales and business development in medical devices companies, mainly in global markets. Amit holds an MD from the Technion Institute, Haifa.



ALBERT GANYUSHIN EURONEXT

Albert is the Head of International Listings at Euronext, the most liquid single order book stock exchange in Europe with listings venues in London, Paris, Amsterdam, Brussels and Lisbon. In 2011–2013, Albert led the EMEA International Listings team of NYSE Euronext and oversaw over 25 IPOs of EMEA-based companies on the New York Stock Exchange. Prior to this Albert was an investment banker with Deutsche Bank, Carlton Partners and Religare Capital Markets. Albert has an MBA from London Business School.

VOTING PANEL



STEFAN HAMILL

PEEL HUNT

Stefan joined Peel Hunt in January 2011, joining forces with Paul Cuddon to form what Peel Hunt believes is the strongest team in UK healthcare and life sciences. Prior to joining Peel Hunt, Stefan was a founder of independent research house Clear Capital (now part of Espirito Santo) where he covered a wide variety of firms across the sector and was ranked No.3 in Extel. Stefan was formerly a strategy consultant and has a PhD in Antibody Engineering from the University of Cambridge.

OSCAR IZEBLOUD

KEMPEN & CO

Oscar joined Kempen & Co, a merchant bank based in Amsterdam, in 2006. He is currently Managing Director Corporate Finance, heading the Life Sciences/Healthcare team. Prior to this Oscar worked as Director Equity Research, covering European listed life sciences companies at Kempen & Co. Oscar has advised on a wide variety of primary and secondary public offerings and M&A transactions across Europe. Before Kempen & Co he worked in various commercial roles in the industry, eventually in business development at Crucell. Oscar obtained his PhD in Pharmacology at TNO in the Netherlands and he holds an MSc degree in Biopharmaceutical Sciences from the University of Leiden.

VOTING PANEL



RENEE AGUIAR-LUCANDER OMEGA FUNDS

Renee joined Omega Funds after serving as a partner in the venture capital group of 3i Group plc in London where, since 2005, she was responsible for managing their publicly quoted assets and the European legacy healthcare portfolio. In addition, whilst at 3i, Renee structured and executed several secondary sale processes. Prior to this she was a Managing Director in Investment Banking at Lehman Brothers, with a focus on Business Media & Internet. Renee has over 12 years of corporate finance experience with firms such as BT Alex Brown, Deutsche Bank and Lehman Brothers, where she focused on raising M&A and private/public capital for growth companies in both Europe and the US. Prior to Investment Banking, Renee worked for five years in European sales and marketing for a financial services focused software business. Renee has a BA in Finance from Stockholm School of Economics and a MBA from INSEAD. She has significant board experience from both private and public board work and is presently a board member of Biosilta Ltd, Egalet Corporation, NsGene A/S, Scibase AB, Simparel and SpineVision SA.

GERALDINE O'KEEFFE LIFE SCIENCES PARTNERS

Geraldine O'Keeffe joined LSP in 2008 and became a partner in 2010. Geraldine's prime focus and responsibility within LSP is to invest in listed securities. Prior to joining LSP, she held the position of Senior Healthcare Analyst at Fortis Investment Banking. In that position, she researched a wide range of innovative life sciences companies, both in Europe and the US. Geraldine brings strong analytical and investment skills to the LSP team. Before joining the financial community, she worked within the life sciences industry for a number of years, gaining first-hand product development experience in a commercial setting. Prior to working in the industry, she lectured in Biomedical Sciences for several years at the Dublin Institute of Technology. Geraldine has a very strong scientific background, including a Bachelor's degree in Biochemistry and Microbiology from University College Cork and a Master's degree in Biotechnology from University College Galway. She also conducted post-graduate research, inter alia at the prestigious Max Planck Institute for Biophysical Chemistry in Göttingen, Germany. In addition, Geraldine is also a graduate of The Dublin School of Business.



VOTING PANEL



DAVID PINNIGER POLAR CAPITAL

David Pinniger is a fund manager with the Polar Capital Healthcare team, and has over 14 years of investment experience in healthcare, specialising in biotechnology. He has managed investments across both venture and specialist funds for firms including SV Life Sciences, Abingworth and Morgan Stanley. David holds a first class honours degree in Human Sciences from the University of Oxford, and is a CFA charterholder.

NICK RODGERS SEHTA

Nick is an experienced non-executive director and chairman with a background as a successful corporate financier. He has considerable experience of businesses in the healthcare, medical, biotechnology environmental and technology sectors.

Nick is Chairman of Oxford BioMedica plc, a leading gene-based biopharmaceutical company. Nick is also chairman of SEHTA Enterprises, the commercial arm of SEHTA, one of the largest health technology networking organisations in the UK. Until March 2013 Nick was the Chief Executive of Ipsos Ventures plc, a creator and investor in early stage technology and healthcare businesses. As such he created eight businesses around university technology.

VOTING PANEL



JULIE SIMMONDS CANACCORD GENUITY

Julie joined Canaccord Genuity when it acquired Collins Stewart in December 2010. Her research coverage focuses on small and mid-cap healthcare companies across medical devices, biotechnology and healthcare services subsectors. Julie joined from Piper Jaffray where she spent five years as a Senior Analyst in the No.1 Extel rated healthcare team covering both UK and European stocks. Prior to Collins Stewart Julie was with Nomura and previously Head of Life Sciences Research at Evolution Securities where she was an analyst from 1998 to 2004. Julie has a PhD in Microbiology from University of Kent at Canterbury. Prior to becoming an analyst Julie gained industrial experience in the biotechnology sector in both Europe and the US.

SACHIN SONI KEMPEN & CO

Sachin currently works as Director Equity Research (Life Sciences) at Kempen & Co where he is responsible for coverage of European healthcare/life sciences sector. He has over eight years of experience in the life sciences industry with an exposure to both private (venture capital) as well as public market investments and has been involved in multiple IPOs/secondary placements.

Sachin started his career as a medical doctor where he worked as a general practitioner with the Indian Red Cross and Max Healthcare Hospital. He was ranked among top 0.1% students at All-India level in Physics and Chemistry and finished his degree in Medicine (MBBS) with honors in Pharmacology and Biochemistry from Seth G S Medical College & KEM Hospital, Mumbai, India. He holds a Master's in Business Administration with concentration in finance from Rotterdam School of Management, the Netherlands/Columbia Business School, US.



VOTING PANEL



MELANIE TOYNE-SEWELL INSTINCTIF PARTNERS

Melanie is a specialist in financial and corporate communications for life science companies and heads up Financial PR for the life sciences team. Prior to Instinctif Partners, Melanie was Head of Healthcare at the Hogarth Partnership, a partner in the Financial Dynamics Life Sciences team and a Director of Merlin Financial. She has extensive experience of capital market transactions and corporate issues facing the pharma, biotech, medtech and healthcare sectors. Before entering the field of financial PR, Melanie was at Price Waterhouse where she qualified as a chartered accountant. She has a BA Hons in Biochemistry from Oxford University.

ELISE WANG DEERFIELD

As a Principal and Analyst on the Private Transactions team, Elise provides extensive research and analysis on individual companies operating in the healthcare industry in both the US and Europe. Prior to joining Deerfield in 2010, Elise began her career in healthcare in 1987 as a venture capitalist and banker at PaineWebber Inc. and was an officer of PaineWebber Development Corporation, which managed nearly \$1.0bn in assets representing three PaineWebber funds and several research and development limited partnerships (RDLPs) invested in biotechnology and high technology companies. From 1996 to 2007, Elise was a Senior Research Analyst and Managing Director in healthcare primarily covering the biotechnology industry at PaineWebber Inc. (1996–2001) and Citigroup (2001–2007). She holds an AB in Engineering Sciences with a specialty in Biomechanics from Harvard University and an MBA from Harvard Business School.

VOTING PANEL



BRIAN WHITE SHORE CAPITAL

Brian is Head of Healthcare at Shore Capital covering the entire spectrum of UK healthcare companies including life sciences, large pharma, medical devices, medical technology and healthcare services. Prior to joining Shore, Brian led the pan-European biotechnology research effort latterly as a Managing Director at Deutsche Bank. Brian has been involved in capital raisings for companies throughout Europe and has been highly ranked in various external surveys including Institutional Investor, Extel and Starmine.